Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Wins Argument In Exclusivity Case, But Not Terazosin Approval

Executive Summary

Mylan will have to wait until after Feb. 9 to launch its generic terazosin capsules even though the company has won a federal court ruling that Geneva's 180-day exclusivity for the product should have already expired.

You may also be interested in...



Barr Fluoxetine Generic Exclusivity Claim Faces Hurdles

Barr's claim to 180 days of generic exclusivity for fluoxetine will depend on the outcome of judicial and regulatory proceedings over the next year.

Barr Fluoxetine Generic Exclusivity Claim Faces Hurdles

Barr's claim to 180 days of generic exclusivity for fluoxetine will depend on the outcome of judicial and regulatory proceedings over the next year.

FDA Ordered To Rescind Barr's 180-Day Exclusivity For Generic Tamoxifen

FDA is ordered to reverse its March 1999 decision to grant Barr's tamoxifen 180-day exclusivity by Washington, D.C. federal court on the grounds that Barr lost its first ANDA filer status when it dropped its patent challenge in a settlement with tamoxifen innovator AstraZeneca.

Related Content

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel